Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01545310 · ClinicalTrials.gov registry record · Phase 1
A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01545310: Completed Phase 1 study of Schizophrenia, sponsored by Abbott.
NCT01545310 is a Phase 1 study of Schizophrenia that has completed, run by Abbott. The registered enrollment target is 18 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01545310, a Phase 1 study of Schizophrenia, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This open-label, Phase 1 study will investigate the 5-hydroxytryptamine 6 (5-HT6) receptor occupancy in the brain using positron emission tomography (PET) following single oral doses of SLV354. Up to 22 healthy male subjects and male subjects with stable schizophrenia, between 18-55 years of age are to complete the study.
Primary Outcome
5-HT6 receptor occupancy and the relationship between SLV354 plasma concentrations and receptor occupancy
Conditions Studied
Interventions
- DRUG SLV354
Study Locations (1)
Connecticut
- Site Reference ID/Investigator# 52162 - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
What the finished NCT01545310 record still lists
NCT01545310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which SLV354 is the first listed.
NCT01545310 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT01545310 about?
NCT01545310 is a clinical study titled "A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia". This open-label, Phase 1 study will investigate the 5-hydroxytryptamine 6 (5-HT6) receptor occupancy in the brain using positron emission tomography (PET) following single oral doses of SLV354. Up to 22 healthy male subjects and male subjects with stable schizophrenia, between 18-55 years of age are...
What is the current status of trial NCT01545310?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-05. Estimated completion is 2012-07.
What conditions does trial NCT01545310 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT01545310?
The interventions under investigation include: SLV354 (DRUG).
Who is sponsoring clinical trial NCT01545310?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01545310 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01545310's enrollment target sits among peer trials
18 294th of 315 higher than 21 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia